Your session is about to expire
← Back to Search
DOTA-5G Pair for Pancreatic Cancer
Study Summary
This trial will test a new theranostic pair to treat pancreatic cancer. The goal is to find out if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had major surgery in the last 28 days and don't plan any in the next 6 weeks.My scans show at least one cancer spot that's clearly visible.Your blood counts need to be at a certain level: ANC (a type of white blood cell) should be at least 1000, platelet count should be at least 100,000, and hemoglobin should be at least 8.I am taking blood thinners other than aspirin.I can take care of myself but might not be able to do heavy physical work.I have severe heart failure.I do not have any ongoing serious infections needing treatment.I finished my last chemotherapy over 2 weeks ago and any side effects have mostly gone.I can stay still for up to an hour.I have another cancer that needed treatment in the last 2 years.I have had radiation therapy for advanced or metastatic disease.My pancreatic cancer is advanced and cannot be removed by surgery.My cancer has worsened after treatment, confirmed by a recent scan.I haven't had serious bleeding in the last two weeks.Your blood test results for AST, ALT, alkaline phosphatase, total bilirubin, and creatinine should not be too high.Your blood clotting tests show abnormal results.I am 18 years old or older.
- Group 1: [177Lu]Lu DOTA-ABM-5G dose escalation therapy study
- Group 2: Recommended Phase 2 dose [177Lu]Lu DOTA-ABM-5G therapy study
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide a comprehensive overview of past experiments utilizing [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G?
"Presently, 30 clinical studies are ongoing for [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. Three of these trials are in their third phase of development. The majority of the research is conducted at Newcastle and Gateshead; however, there exist an additional 238 locations across the globe exploring this revolutionary treatment option."
What is the upper cap of participants for this trial?
"Affirmative. According to information hosted on clinicaltrials.gov, the trial is still recruiting participants after it was posted on December 18th 2020 and last modified on April 21st 2022. Recruitment will take place at a single site with 30 patients in total needed for participation."
Are there any vacancies available for participants in this investigation?
"Affirmative. Clinicaltrials.gov officially lists this medical trial as actively recruiting patients since December 18th 2020, with the last update on April 21st 2022. The research team requires at least 30 people to be recruited from a single site."
Share this study with friends
Copy Link
Messenger